LLYEli Lilly and CompanyRunning, no new patients
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
Lymphoma, Non-Hodgkin · Leukemia, Lymphocytic, Chronic, B-Cell · B-cell Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 13 (planned)
- Started
- Aug 7, 2025
- Main results expected
- May 2030
- Fully finished
- May 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants with Grade 3 or Higher Treatment-emergent Adverse Events
Measured over: Day 1 through 28 days after last dose or start of new anticancer therapy
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07162181 · record last updated 2026-04-17 · checked 2026-11-09 15:36 UTC